Inge Verbrugge

Inge Verbrugge

Johnson & Johnson Co. - New Jersey / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4396948
-
person_outline Inge Verbrugge's MOST POPULAR ARTICLES
1-) Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodiesI Verbrugge, J Hagekyriakou, LL Sharp, M Galli, A West, NM McLaughlin, ...Cancer research 72 (13), 3163-3174, 20122672012
2-) Combination approaches with immune-checkpoint blockade in cancer therapyM Swart, I Verbrugge, JB BeltmanFrontiers in oncology 6, 233, 20161332016
3-) Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMA Deken, J Gadiot, ES Jordanova, R Lacroix, M van Gool, P Kroon, ...Oncoimmunology 5 (12), e1238557, 20161262016
4-) Differentiation therapy for the treatment of t (8; 21) acute myeloid leukemia using histone deacetylase inhibitorsM Bots, I Verbrugge, BP Martin, JM Salmon, M Ghisi, A Baker, K Stanley, ...Blood, The Journal of the American Society of Hematology 123 (9), 1341-1352, 20141392014
5-) The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemiaA Baker, GP Gregory, I Verbrugge, L Kats, JJ Hilton, E Vidacs, EM Lee, ...Cancer research 76 (5), 1158-1169, 20161212016